Pentoxifylline
Pentoxifylline is a methylxanthine haemorheologic agent that improves microcirculatory blood flow, licensed for intermittent claudication. It is a non-selective phosphodiesterase inhibitor and is used off-label in the PED and men's-health space for erectile support, vascular 'pump' and, on weaker evidence, to soften Peyronie's plaques. It is oral, well tolerated and not a controlled substance.
01 Overview
Pentoxifylline reduces blood viscosity and improves red-cell flexibility, increasing flow through small vessels; it also inhibits phosphodiesterase (raising cAMP/cGMP) and has anti-TNF-alpha and mild antifibrotic activity. Its licensed use is intermittent claudication, where it modestly increases pain-free walking distance.
In men's health it is used off-label for its microvascular and antifibrotic effects — as an adjunct for vasculogenic erectile dysfunction and, with limited evidence, for Peyronie's disease. Bodybuilders sometimes use it for peripheral vasodilation/'pump'. It is generally well tolerated, with gastrointestinal upset the main complaint, and shares the class caution around bleeding and hypotension.
02 Mechanism
Non-selective phosphodiesterase inhibitor and haemorheologic agent: raises cAMP/cGMP, lowers blood viscosity, increases erythrocyte deformability and has anti-TNF-alpha/antifibrotic effects.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Off-label vascular/ED support | 400–1200 mg/day | Oral | Same dose range used off-label; evidence for ED/Peyronie's is limited. |
| Claudication (label) | 400–1200 mg/day | Oral | Usually 400 mg two to three times daily with food. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Improved microcirculatory flowImproves pain-free walking distance in claudication; increases peripheral microvascular flow. | modest | Clinical | |
| Antifibrotic / possible Peyronie's benefitLimited data suggest it may reduce plaque size/curvature in Peyronie's disease; evidence is weak. | small | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Gastrointestinal upsetNausea, dyspepsia and bloating are the most frequent complaints. | Mild | Common | Clinical | |
| Dizziness / flushingLightheadedness and flushing from vasodilation. | Mild | Uncommon | Clinical | |
| Bleeding riskReduced blood viscosity and platelet effects can increase bleeding, especially with anticoagulants. | Moderate | Uncommon | Clinical |